Cost-effectiveness analysis of surgical lung volume reduction compared with endobronchial valve treatment in patients with severe emphysema

被引:1
作者
Franzen, Daniel [1 ,2 ]
Bodmer, Christa [1 ]
Ehrenbaum, Simon [3 ]
Steinack, Carolin [1 ]
Opitz, Isabelle [4 ]
Docter, Katrin [5 ]
Schoffski, Oliver [5 ]
机构
[1] Univ Hosp Zurich, Dept Pulmonol, Zurich, Switzerland
[2] Spital Uster, Dept Internal Med, Uster, Switzerland
[3] Univ Hosp Zurich, Div Heart Vessel & Thorax, Zurich, Switzerland
[4] Univ Hosp Zurich, Dept Thorac Surg, Zurich, Switzerland
[5] Friedrich Alexander Univ, Sch Business Econ & Soc, Div Hlth Management, Nurnberg, Germany
关键词
WELL-BEING SCALE; OBSTRUCTIVE PULMONARY-DISEASE; CLINICAL-TRIALS; SURGERY; QUALITY; HEALTH; PREVALENCE; VALIDITY; OUTCOMES; THERAPY;
D O I
10.57187/smw.2022.40008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Lung volume reduction, either by surgery or bronchoscopically by endobronchial valve treatment have been shown to be a cost-effective alternative compared with conservative therapy. However, there is no comparative analysis of lung volume reduction by surgery and bronchoscopic lung volume reduction using endobronchial valves. OBJECTIVES: The aim of this retrospective study was to provide a cost-effectiveness analysis of lung volume reduction by surgery compared with bronchoscopic lung volume reduction using endobronchial valves. METHODS: The effectiveness of lung volume reduction was assessed using forced expiratory volume in the first second (FEV1), residual volume (RV) and 6-minute walking distance (6MWD), measured at baseline and at 4 to 12 weeks. Cost unit accounting derived from SwissDRG was used as a surrogate of the costs from the payer's perspective. RESULTS: In total, 67 patients (37 men and 30 women) with a mean age of 68.3 +/- 7.4 years were included. Both clinical effectiveness and costs were comparable between surgical and bronchoscopic lung reduction. The incremental cost-effectiveness ratios (ICERs) for bronchoscopic compared with lung volume reduction by surgery for FEV1, RV and 6MWD were -101, 4 and 58, respectively. For RV and 6MWD, it could be shown that endobronchial valve treatment is justified as a probably cost-effective alternative to lung volume reduction by surgery. Endobronchial valve treatment resulted in an improvement of 0.25 quality-adjusted life years (QALYs) and an ICER of (sic) 7657 per QALY gained. CONCLUSION: A robust statement on the superiority of one of the two procedures in terms of cost-effectiveness cannot be made from the present study. Therefore, the study is not suitable for resource allocation. Two upcoming trials comparing lung volume reduction surgery and endobronchial valve treatment may be able to answer this question.
引用
收藏
页数:11
相关论文
共 41 条
[11]   Survival after Endobronchial Valve Placement for Emphysema: A 10-Year Follow-up Study [J].
Garner, Justin ;
Kemp, Samuel V. ;
Toma, Tudor P. ;
Hansell, David M. ;
Polkey, Michael I. ;
Shah, Pallav L. ;
Hopkinson, Nicolas S. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 194 (04) :519-521
[12]  
Global Initiative for Obstructive Lung Disease. GOLD, 2017, POCKET GUIDE COPD DI
[13]   Cost-effectiveness of endobronchial valve treatment in patients with severe emphysema compared to standard medical care [J].
Hartman, Jorine E. ;
Klooster, Karin ;
Groen, Henk ;
ten Hacken, Nick H. T. ;
Slebos, Dirk-Jan .
RESPIROLOGY, 2018, 23 (09) :835-841
[14]   Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort [J].
Herth, Felix J. F. ;
Noppen, Marc ;
Valipour, Arschang ;
Leroy, Sylvie ;
Vergnon, Jean-Michel ;
Ficker, Joachim H. ;
Egan, Jim J. ;
Gasparini, Stefano ;
Agusti, Carlos ;
Holmes-Higgin, Debby ;
Ernst, Armin .
EUROPEAN RESPIRATORY JOURNAL, 2012, 39 (06) :1334-1342
[15]   Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force [J].
Husereau, Don ;
Drummond, Michael ;
Petrou, Stavros ;
Carswell, Chris ;
Moher, David ;
Greenberg, Dan ;
Augustovski, Federico ;
Briggs, Andrew H. ;
Mauskopf, Josephine ;
Loder, Elizabeth .
VALUE IN HEALTH, 2013, 16 (02) :231-250
[16]   Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review [J].
Iheanacho, Ike ;
Zhang, Shiyuan ;
King, Denise ;
Rizzo, Maria ;
Ismaila, Afisi S. .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 :439-460
[17]   Minimal Clinically Important Differences in Pharmacological Trials [J].
Jones, Paul W. ;
Beeh, Kai M. ;
Chapman, Kenneth R. ;
Decramer, Marc ;
Mahler, Donald A. ;
Wedzicha, Jadwiga A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189 (03) :250-255
[18]   Outcomes and markers in the assessment of chronic obstructive pulmonary disease [J].
Jones, PW ;
Agusti, AGN .
EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (04) :822-832
[19]   VALIDITY OF A QUALITY OF WELL-BEING SCALE AS AN OUTCOME MEASURE IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
KAPLAN, RM ;
ATKINS, CJ ;
TIMMS, R .
JOURNAL OF CHRONIC DISEASES, 1984, 37 (02) :85-95
[20]   VALIDITY OF THE QUALITY OF WELL-BEING SCALE FOR PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
KAPLAN, RM ;
ANDERSON, JP ;
PATTERSON, TL ;
MCCUTCHAN, JA ;
WEINRICH, JD ;
HEATON, RK ;
ATKINSON, JH ;
THAL, L ;
CHANDLER, J ;
GRANT, I .
PSYCHOSOMATIC MEDICINE, 1995, 57 (02) :138-147